Our lead candidate is a topically applied patidegib gel designed to prevent the development of new basal cell carcinoma (BCC) lesions. We push the boundaries of medical dermatology to …

2024年5月16日 · Sol-Gel developed TWYNEO, which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older, and EPSOLAY, …

Sol-Gel Technologies is an experienced dermatology company that is leveraging innovative approaches to develop advanced treatments for patients with severe skin conditions.

With a focus on expediting the development of effective dermatological solutions, we leverage our expertise to identify, evaluate, develop, and commercialize products that have the potential to …

2024年5月16日 · Sol-Gel Technologies, Ltd. 是一家皮肤科公司，专注于发现、开发、商业化或合作治疗皮肤病的药物。 Sol-Gel 开发了 TWYNEO®（经FDA批准用于治疗9岁及以上儿童和成 …

NESS ZIONA, Israel, May 20, 2024 (GLOBE NEWSWIRE) -- Sol- Gel Technologies, Ltd. (NASDAQ: SLGL), a dermatology company, pioneering treatments for patients with severe …

2024年5月16日 · Sol-Gel Technologies, Ltd. announced that it has signed an asset purchase agreement with Chinese based Shenzhen Beimei Pharmaceutical Co. Ltd, for the …

Sol-Gel Technologies (NASDAQ: SLGL) is a clinical-stage dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the …

2023年6月6日 · Sol-Gel to receive up to $11 million in upfront payments and regulatory and sales milestones for both drugs, combined, plus additional royalties ranging from low double-digits to …

2023年6月6日 · Sol-Gel developed TWYNEO which is approved by the FDA for the treatment of acne vulgaris in adults and pediatric patients nine years of age and older; and EPSOLAY, …